Valisure's Engagement With Congressman Rosa DeLauro

Valisure expresses its gratitude for the longstanding collaboration with Congresswoman Rosa DeLauro, representing Connecticut’s Third Congressional District. Congresswoman DeLauro has demonstrated a steadfast commitment to advancing biomedical research, advocating for increased funding to facilitate groundbreaking advancements in science and medicine, aligning closely with Valisure's mission.
Of particular note is Congresswoman DeLauro's relentless advocacy for the Recall Unsafe Drugs Act, a legislative initiative aimed at empowering the FDA to enforce mandatory recalls of products linked to severe health consequences or mortality. This dedication was evident in her joint communication with David Light to FDA Commissioner Stephen Hahn and HHS Secretary Alex Azar, urging the recall of ranitidine-containing drugs due to elevated levels of N-Nitrososdimethylamine (“NDMA”), a probable human carcinogen.
Furthermore, Congresswoman DeLauro actively participated in press conferences, webinars, and public awareness campaigns alongside industry experts such as David Light, Joe Graedon, and Dr. Jon Ernstoff. Her collaboration was pivotal in addressing public health concerns related to the contamination of drugs, with a particular focus on ranitidine, as evidenced by her involvement in events like Joe Graedon’s webinar and CBS' The Doctors interview.
A significant milestone in this advocacy journey was achieved on February 4, 2022, with the inclusion of a provision in the America COMPETES Act, granting the FDA mandatory recall authority over drug products. Valisure applauds Congresswoman DeLauro for her unwavering efforts and emphasizes the importance of regulatory measures to enhance the quality and safety of the U.S. drug supply.
More recently, on March 7th, 2022, Congresswoman DeLauro addressed FDA Commissioner Robert Califf, seeking clarification on the agency's intentions regarding an investigation into GlaxoSmithKline’s actions concerning Zantac. This inquiry follows previous revelations about NDMA contamination in ranitidine and subsequent market removal. DeLauro's letter underscores the need for accountability and investigative action in light of recent developments, as reported by Bloomberg.
Valisure remains committed to supporting Congresswoman DeLauro's efforts to safeguard public health and improve the integrity of the global drug supply chain.

Valisure's Engagement With Congressman Rosa DeLauro

December 18, 2019

Valisure expresses its gratitude for the longstanding collaboration with Congresswoman Rosa DeLauro, representing Connecticut’s Third Congressional District. Congresswoman DeLauro has demonstrated a steadfast commitment to advancing biomedical research, advocating for increased funding to facilitate groundbreaking advancements in science and medicine, aligning closely with Valisure's mission.
Of particular note is Congresswoman DeLauro's relentless advocacy for the Recall Unsafe Drugs Act, a legislative initiative aimed at empowering the FDA to enforce mandatory recalls of products linked to severe health consequences or mortality. This dedication was evident in her joint communication with David Light to FDA Commissioner Stephen Hahn and HHS Secretary Alex Azar, urging the recall of ranitidine-containing drugs due to elevated levels of N-Nitrososdimethylamine (“NDMA”), a probable human carcinogen.
Furthermore, Congresswoman DeLauro actively participated in press conferences, webinars, and public awareness campaigns alongside industry experts such as David Light, Joe Graedon, and Dr. Jon Ernstoff. Her collaboration was pivotal in addressing public health concerns related to the contamination of drugs, with a particular focus on ranitidine, as evidenced by her involvement in events like Joe Graedon’s webinar and CBS' The Doctors interview.
A significant milestone in this advocacy journey was achieved on February 4, 2022, with the inclusion of a provision in the America COMPETES Act, granting the FDA mandatory recall authority over drug products. Valisure applauds Congresswoman DeLauro for her unwavering efforts and emphasizes the importance of regulatory measures to enhance the quality and safety of the U.S. drug supply.
More recently, on March 7th, 2022, Congresswoman DeLauro addressed FDA Commissioner Robert Califf, seeking clarification on the agency's intentions regarding an investigation into GlaxoSmithKline’s actions concerning Zantac. This inquiry follows previous revelations about NDMA contamination in ranitidine and subsequent market removal. DeLauro's letter underscores the need for accountability and investigative action in light of recent developments, as reported by Bloomberg.
Valisure remains committed to supporting Congresswoman DeLauro's efforts to safeguard public health and improve the integrity of the global drug supply chain.

Valisure's Engagement With Congressman Rosa DeLauro

Valisure expresses its gratitude for the longstanding collaboration with Congresswoman Rosa DeLauro, representing Connecticut’s Third Congressional District. Congresswoman DeLauro has demonstrated a steadfast commitment to advancing biomedical research, advocating for increased funding to facilitate groundbreaking advancements in science and medicine, aligning closely with Valisure's mission.
Of particular note is Congresswoman DeLauro's relentless advocacy for the Recall Unsafe Drugs Act, a legislative initiative aimed at empowering the FDA to enforce mandatory recalls of products linked to severe health consequences or mortality. This dedication was evident in her joint communication with David Light to FDA Commissioner Stephen Hahn and HHS Secretary Alex Azar, urging the recall of ranitidine-containing drugs due to elevated levels of N-Nitrososdimethylamine (“NDMA”), a probable human carcinogen.
Furthermore, Congresswoman DeLauro actively participated in press conferences, webinars, and public awareness campaigns alongside industry experts such as David Light, Joe Graedon, and Dr. Jon Ernstoff. Her collaboration was pivotal in addressing public health concerns related to the contamination of drugs, with a particular focus on ranitidine, as evidenced by her involvement in events like Joe Graedon’s webinar and CBS' The Doctors interview.
A significant milestone in this advocacy journey was achieved on February 4, 2022, with the inclusion of a provision in the America COMPETES Act, granting the FDA mandatory recall authority over drug products. Valisure applauds Congresswoman DeLauro for her unwavering efforts and emphasizes the importance of regulatory measures to enhance the quality and safety of the U.S. drug supply.
More recently, on March 7th, 2022, Congresswoman DeLauro addressed FDA Commissioner Robert Califf, seeking clarification on the agency's intentions regarding an investigation into GlaxoSmithKline’s actions concerning Zantac. This inquiry follows previous revelations about NDMA contamination in ranitidine and subsequent market removal. DeLauro's letter underscores the need for accountability and investigative action in light of recent developments, as reported by Bloomberg.
Valisure remains committed to supporting Congresswoman DeLauro's efforts to safeguard public health and improve the integrity of the global drug supply chain.
Valisure expresses its gratitude for the longstanding collaboration with Congresswoman Rosa DeLauro, representing Connecticut’s Third Congressional District. Congresswoman DeLauro has demonstrated a steadfast commitment to advancing biomedical research, advocating for increased funding to facilitate groundbreaking advancements in science and medicine, aligning closely with Valisure's mission.
Of particular note is Congresswoman DeLauro's relentless advocacy for the Recall Unsafe Drugs Act, a legislative initiative aimed at empowering the FDA to enforce mandatory recalls of products linked to severe health consequences or mortality. This dedication was evident in her joint communication with David Light to FDA Commissioner Stephen Hahn and HHS Secretary Alex Azar, urging the recall of ranitidine-containing drugs due to elevated levels of N-Nitrososdimethylamine (“NDMA”), a probable human carcinogen.
Furthermore, Congresswoman DeLauro actively participated in press conferences, webinars, and public awareness campaigns alongside industry experts such as David Light, Joe Graedon, and Dr. Jon Ernstoff. Her collaboration was pivotal in addressing public health concerns related to the contamination of drugs, with a particular focus on ranitidine, as evidenced by her involvement in events like Joe Graedon’s webinar and CBS' The Doctors interview.
A significant milestone in this advocacy journey was achieved on February 4, 2022, with the inclusion of a provision in the America COMPETES Act, granting the FDA mandatory recall authority over drug products. Valisure applauds Congresswoman DeLauro for her unwavering efforts and emphasizes the importance of regulatory measures to enhance the quality and safety of the U.S. drug supply.
More recently, on March 7th, 2022, Congresswoman DeLauro addressed FDA Commissioner Robert Califf, seeking clarification on the agency's intentions regarding an investigation into GlaxoSmithKline’s actions concerning Zantac. This inquiry follows previous revelations about NDMA contamination in ranitidine and subsequent market removal. DeLauro's letter underscores the need for accountability and investigative action in light of recent developments, as reported by Bloomberg.
Valisure remains committed to supporting Congresswoman DeLauro's efforts to safeguard public health and improve the integrity of the global drug supply chain.

SIGN UP FOR THE VALISURE NEWSLETTER 

Sign up to stay updated with Valisure announcements, relevant industry news, company updates, and more. 

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.